[Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].
Ralf
R
Gutzmer
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000378:metabolism; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors*; D058990:Molecular Targeted Therapy / Q000379:methods; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
D000970:Antineoplastic Agents; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020929:Mitogen-Activated Protein Kinase Kinases